Helix BioPharma (HBP) Competitors C$0.67 -0.03 (-4.29%) (As of 12:00 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarnings HBP vs. MDNA, ONC, COV, SCYB, COM, NVH, IGX, SVA, TH, and PDPShould you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include Medicenna Therapeutics (MDNA), Oncolytics Biotech (ONC), Covalon Technologies (COV), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Sernova (SVA), Theratechnologies (TH), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry. Helix BioPharma vs. Medicenna Therapeutics Oncolytics Biotech Covalon Technologies Scythian Biosciences 138267 (COM.TO) Novoheart IntelGenx Technologies Sernova Theratechnologies Pediapharm Medicenna Therapeutics (TSE:MDNA) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk. Which has more risk and volatility, MDNA or HBP? Medicenna Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Helix BioPharma has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500. Is MDNA or HBP more profitable? Medicenna Therapeutics' return on equity of -105.43% beat Helix BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Medicenna TherapeuticsN/A -105.43% -32.80% Helix BioPharma N/A -2,220.62%-279.98% Does the media refer more to MDNA or HBP? In the previous week, Medicenna Therapeutics had 2 more articles in the media than Helix BioPharma. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Helix BioPharma. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score. Company Overall Sentiment Medicenna Therapeutics Neutral Helix BioPharma Neutral Which has higher earnings and valuation, MDNA or HBP? Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicenna TherapeuticsN/AN/A-C$26.24M-C$0.38-4.08Helix BioPharmaN/AN/A-C$6.14M-C$0.20-3.35 Does the MarketBeat Community believe in MDNA or HBP? Medicenna Therapeutics received 22 more outperform votes than Helix BioPharma when rated by MarketBeat users. Likewise, 68.22% of users gave Medicenna Therapeutics an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote. CompanyUnderperformOutperformMedicenna TherapeuticsOutperform Votes8868.22% Underperform Votes4131.78% Helix BioPharmaOutperform Votes6663.46% Underperform Votes3836.54% Do institutionals & insiders hold more shares of MDNA or HBP? 13.0% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryMedicenna Therapeutics beats Helix BioPharma on 8 of the 11 factors compared between the two stocks. Ad Darwin2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Get Helix BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HBP vs. The Competition Export to ExcelMetricHelix BioPharmaBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$32.84MC$163.50MC$5.10BC$6.20BDividend Yield1.50%3.50%5.04%5.31%P/E Ratio-3.35329.4795.1226.60Price / SalesN/A14,863.411,217.301,488.52Price / Cash11.3211.6739.4982.35Price / Book-67.007.066.973.13Net Income-C$6.14M-C$18.37MC$118.73MC$292.70M7 Day Performance-1.47%0.21%-1.22%1.40%1 Month Performance-37.38%8.28%-3.07%13.24%1 Year Performance191.30%25.08%32.52%44.39% Helix BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HBPHelix BioPharmaN/AC$0.67-4.3%N/A+211.1%C$32.84MN/A-3.359Gap DownMDNAMedicenna TherapeuticsN/AC$1.55+3.3%N/A+252.9%C$118.47MN/A-3.9520Gap UpONCOncolytics Biotech1.4019 of 5 starsC$1.38-1.4%C$3.50+153.6%-34.6%C$106.07MN/A-3.6829Analyst RevisionCOVCovalon TechnologiesN/AC$3.83-1.8%N/A+271.4%C$104.94MC$29.20M-97.50N/ASCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/A+0.0%C$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423,500.00-13.95N/AIGXIntelGenx TechnologiesN/AC$0.58+1.8%N/A+0.0%C$87.32MC$1.75M-7.442,050Gap UpSVASernovaN/AC$0.24flatC$1.83+663.9%-66.7%C$78.08MN/A-1.851,959Gap DownTHTheratechnologiesN/AC$1.68-1.2%N/A-9.6%C$77.25MC$82.57M-9.44103PDPPediapharmN/AC$0.30+1.7%N/A+0.0%C$66.36MC$11.16M-4.11N/A Related Companies and Tools Related Companies Medicenna Therapeutics Competitors Oncolytics Biotech Competitors Covalon Technologies Competitors Scythian Biosciences Competitors 138267 (COM.TO) Competitors Novoheart Competitors IntelGenx Technologies Competitors Sernova Competitors Theratechnologies Competitors Pediapharm Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:HBP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
